Clinical Trial Update: Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine [Phase 2]

View source ↗

Summary

A Phase 2 trial of irinotecan in patients with advanced/metastatic breast cancer after failure of an anthracycline, a taxane, and capecitabine has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Irinotecan (Camptosar) (Irinotecan)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED